We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Nucleis will Present its RNAi Technology

Nucleis will Present its RNAi Technology

Nucleis will Present its RNAi Technology

Nucleis will Present its RNAi Technology

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nucleis will Present its RNAi Technology "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nucleis has announced that it has offered knock down (RNAi) in vivo mouse model and is currently developing alternatives for conditional and inducible in vivo knock down (RNAi) expression.

Nucleis thanks to a proprietary innovative technology called Speedy Mouse Technology which allows the generation of models in two months.

Speedy Mouse RNAi Technology is based on targeted transgenesis of short hairpin RNA construct into hprt permissive locus of proprietary ES cells, called BPES cells.

These cells demonstrate high potency to colonize wild type blastocyst leading to 100% chimeric mice with 100% germ line transmission.

Single copy integration of shRNA constructs through targeted transgenesis in BPES cells appears to be as efficient as random transgenesis but powerful in term of time, reproducibility and predictability.

Exclusive results of the efficiency, stability and inheritability of the Speedy Mouse® RNAi Technology will be presented at “RNAi Europe meeting” in Amsterdam on September 29th and later in Boston on October 18th for the 4th Annual Discovery on Target.